DIRC1: A Promising Drug Target and Biomarker for Renal Carcinoma

Target Name: DIRC1

NCBI ID: G116093

DIRC1

Other Name(s): Disrupted in renal carcinoma 1 | Disrupted in renal cancer protein | Disrupted in renal carcinoma protein 1 | DIRC1_HUMAN | disrupted in renal carcinoma 1

DIRC1: A Promising Drug Target and Biomarker for Renal Carcinoma

Introduction

Renal cancer is a leading cause of cancer-related mortality worldwide, with a high incidence of uveal, renal, and pelvic cancers. According to the World Health Organization (WHO), the number of new cases of renal cancer worldwide increased from 17,462 in 2012 to 21,277 in 2019, with a 17.8% increase in incidence per year. The rising incidence of renal cancer highlights the urgent need for new treatments and better understanding of the underlying causes.

DIRC1, a gene named after its discovery, has been identified as a promising drug target and biomarker for renal carcinoma. In this article, we will explore the biology of DIRC1, its potential as a drug target, and its potential as a biomarker for renal carcinoma. cancer.

The biology of DIRC1

DIRC1 is a gene that encodes a protein known as DIRC1, which is expressed in various tissues and organs, including the kidneys, adrenal glands, and breast tissue. The protein DIRC1 is composed of four transmembrane domains (TMDs) and a cytoplasmic tail.

DIRC1 is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival. It plays a role in the development and progression of renal cancer by promoting the growth, survival, and angiogenesis of cancer cells.

DIRC1 has been shown to promote the formation of blood-brain barrier (BBB) 鈥嬧?媔n cancer cells, which is a barrier that separates the brain from the rest of the body and is designed to protect it from harmful substances. The formation of the BBB has been linked to the development of resistance to anti-cancer drugs in cancer cells.

DIRC1 has also been shown to promote the formation of cancer-infiltrating immune cells (CIMC), which are immune cells that can infiltrate and survive within cancer cells. The presence of CIMC is associated with a higher risk of cancer progression and poorer prognosis.

DIRC1 has been implicated in the development and progression of various types of cancer, including renal carcinoma. For example, studies have shown that high expression of DIRC1 is associated with poor prognosis in patients with renal cell carcinoma (RCC).

The potential as a drug target

DIRC1's role in the development and progression of cancer makes it an attractive target for drug development. Several studies have shown that inhibiting DIRC1 can inhibit the growth and survival of cancer cells, including RCC.

One of the main compounds that has been shown to inhibit DIRC1 is DIRC1 inhibitor JNJ-752605. This compound is a small molecule that blocks the activity of DIRC1 and has been shown to be effective in preclinical studies against RCC.

Another compound that has been shown to inhibit DIRC1 is DIRC1 inhibitor Loxosome-associated protein (LAP), a protein that is expressed in various tissues and is involved in the formation of the BBB. LAP has been shown to inhibit the activity of DIRC1 and has been shown to be effective in preclinical studies against RCC.

The potential as a biomarker

DIRC1 has also been shown to be a potential biomarker for renal cancer. The expression of DIRC1 has been shown to be elevated in various types of cancer, including RCC. This suggests that DIRC1 may be a useful biomarker for RCC.

DIRC1 has been shown to be expressed in various types of cancer, including RCC, and has been associated with the development and progression of these cancers. The expression of DIRC1 may be a useful biomarker for identifying individuals at risk for RCC and for monitoring the effectiveness of cancer treatments.

Conclusion

DIRC1 is a gene that has

Protein Name: Disrupted In Renal Carcinoma 1

The "DIRC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIRC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets